THRX Stock Overview
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.94|
|52 Week High||US$24.54|
|52 Week Low||US$8.65|
|1 Month Change||-1.00%|
|3 Month Change||-38.18%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-46.50%|
Recent News & Updates
|THRX||US Pharmaceuticals||US Market|
Return vs Industry: Insufficient data to determine how THRX performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how THRX performed against the US Market.
|THRX Average Weekly Movement||22.4%|
|Pharmaceuticals Industry Average Movement||10.6%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: THRX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.
Volatility Over Time: Insufficient data to determine THRX's volatility change over the past year.
About the Company
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-variant inhibitor for activating and resistance mutations of the KIT kinase or a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.
Theseus Pharmaceuticals Fundamentals Summary
|THRX fundamental statistics|
Is THRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|THRX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.57|
|Net Profit Margin||0.00%|
How did THRX perform over the long term?See historical performance and comparison
Is Theseus Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Theseus Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Theseus Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Theseus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: THRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: THRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: THRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: THRX is forecast to have no revenue next year.
High Growth Revenue: THRX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if THRX's Return on Equity is forecast to be high in 3 years time
How has Theseus Pharmaceuticals performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: THRX is currently unprofitable.
Growing Profit Margin: THRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if THRX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare THRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: THRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: THRX has a negative Return on Equity (-23.66%), as it is currently unprofitable.
How is Theseus Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: THRX's short term assets ($91.5M) exceed its short term liabilities ($5.7M).
Long Term Liabilities: THRX's short term assets ($91.5M) exceed its long term liabilities ($903.0K).
Debt to Equity History and Analysis
Debt Level: THRX is debt free.
Reducing Debt: THRX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: THRX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: THRX has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 70.7% each year.
What is Theseus Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate THRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate THRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if THRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if THRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of THRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tim Clackson (56 yo)
Dr. Timothy P. Clackson, also known as Tim, Ph D., is a Director at Elevation Oncology, Inc. since May 2020. Dr. Clackson serves as the Chief Executive Officer and President at Theseus Pharmaceuticals, Inc...
Experienced Management: THRX's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Experienced Board: THRX's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: THRX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: THRX only recently listed within the past 12 months.
Theseus Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Theseus Pharmaceuticals, Inc.
- Ticker: THRX
- Exchange: NasdaqGS
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$375.605m
- Shares outstanding: 37.79m
- Website: https://theseusrx.com
Number of Employees
- Theseus Pharmaceuticals, Inc.
- 245 Main Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/19 23:51|
|End of Day Share Price||2022/01/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.